CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Panelists conclude that sNfL can be used as a biomarker to assess response to
treatment in future trials. In the clinic setting, it could become valuable in directing
therapy; for example, in cases in which the patient is absent clinical signs of aggressive
MS and it’s unclear if they will benefit from infused, injected, or oral disease-modifying
therapy.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
